Skip to main content

ALLERGAN

No ongoing recalls currently shown

Based on the official records currently available to Public Health Trace, no recalls naming ALLERGAN are currently shown as ongoing. The 4 records below are historical recall records.

Public Health Trace has 4 recalls naming ALLERGAN as the recalling firm, republished from official FDA and USDA sources.

Recall history - 4 terminated records

Recalls by year

A bar chart of the number of recalls naming this company by year.

Recalls by year
YearRecalls
20184
Download CSV

FDA Recall TerminatedTerminated: April 6, 2020Historical recordClass II

INFed (Iron Dextran Injection USP) 100 mg elemental iron/2 mL (50 mg/mL), Rx only, packaged in 2 mL Sterile Single Dose Vial, Mfd by Patheon Italia S.p.A. Ferentino, Italy NDC 52544-931-07

by ALLERGAN

Reason
Failed Stability Specification: out of specification for iron content.
Published
December 5, 2018
Distribution
Product was distributed throughout the U…

View recall →

FDA Recall TerminatedTerminated: April 8, 2020Historical recordClass II

INFeD (Iron Dextran Injection USP) 100 mg elemental iron/2 ml (50 mg/mL), Rx Only, packaged in a) single dose vials, (NDC 52544-931-07), b) carton of 10 x 2 ml Single Dose Vials (NDC 52544-931-02) Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054, Manufactured by: Patheon Italia S.p.A. Ferentino, Italy 03013.

by ALLERGAN

Reason
Failed Stability Specifications: Product stability testing results did not meet specifications for iron content.
Published
March 7, 2018
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: February 7, 2019Historical recordClass III

NORCO (Hydrocodone Bitartrate and Acetaminophen) Tablets, USP, 10 mg/325 mg, 100-count bottles, Rx Only, Distributed by: Allergan USA, Inc., Irvine, CA 92612, NDC 0023-6022-01.

by ALLERGAN

Reason
Labeling: Not Elsewhere Classified: does not have the required "CII" controlled drug classification indication on the primary label.
Published
February 21, 2018
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: June 20, 2019Historical recordClass II

Viokace (pancrelipase) tablets, 20,880 USP units, 100-count bottle, Rx only, Distributed by; Allergan USA Inc., Irvine, CA 92612, Manufactured in Canada, NDC 58914-117-10

by ALLERGAN

Reason
Subpotent Drug: One lot of Viokace is being recalled since product stability testing results did not meet the specifications for enzyme profile.
Published
January 17, 2018
Distribution
Nationwide

View recall →

Showing 1–4 of 4 results

Some FDA recall records on this page come from FDA's Enforcement Report database. Not every Enforcement Report record has a separate FDA.gov recall-announcement page.

This page lists recalls that name ALLERGAN as the recalling firm in the official source notice. It is not a safety rating, ranking, or statement that the company acted negligently. Read the full medical disclaimer.